Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, open-label study to investigate the efficacy
and safety of eltrombopag plus recombinant human thrombopoietin (rhTPO) versus eltrombopag as
treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) during the
COVID-19 pandemic.